News | Vascular Closure Devices | May 10, 2018

Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial

Satellite symposium at Heart Rhythm Society 2018 to feature results of the AMBULATE IMPACT Study focused on early ambulation following cardiac ablation to treat atrial fibrillation

Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial

May 10, 2018 — Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the company’s AMBULATE series. The AMBULATE series is studying the Vascade MVP Venous Vascular Closure System for use in the closure of mid-bore (6-12 Fr inner diameter sheath) venous access sites.

AMBULATE is a randomized, multi-center study evaluating the Vascade MVP System compared to manual compression for multi-access, catheter-based procedures such as cardiac ablation for atrial fibrillation. The goal of the trial is to demonstrate significantly reduced time-to-ambulation for patients following these common and high-growth electrophysiology procedures.

Twenty-nine physicians enrolled 204 patients in the AMBULATE pivotal trial at 13 sites across the United States. Principal investigators include:

  • Andrea Natale, M.D., executive medical director, Texas Cardiac Arrhythmia Institute;
  • Mintu Turakhia, M.D., associate professor, Stanford University School of Medicine; and
  • Steve Compton, M.D., Alaska Heart and Vascular Institute.

“Cardiac ablation is a very successful procedure for treating atrial fibrillation. However, patients frequently suffer back pain from the extended bed rest required and pain at the venous access sites due to manual compression,” said Natale. “With the AMBULATE trial, our objective is to demonstrate the ability of the Vascade MVP system to provide a substantial reduction in bed rest time and eliminate the need for manual compression following an ablation procedure.”

Additional studies in the AMBULATE series include:

  • AMBULATE IMPACT Study – a recently completed study that examines today’s workflow following ablation procedures, with a focus on improving hospital economics through early patient ambulation. Data from AMBULATE IMPACT will be presented during a Satellite Symposium at the 2018 Heart Rhythm Society (HRS) Scientific Sessions, May 9-12 in Boston;
  • AMBULATE CE Study – a single-arm study of the Vascade MVP System that was submitted to support the pending CE Mark in the European Union. Forty patients were enrolled by 11 physicians at five sites; and
  • AMBULATE CAP Study – a continued access protocol study designed to evaluate the Vascade MVP System for enabling earlier hospital discharge and other endpoints in the setting of electrophysiology procedures. The AMBULATE CAP protocol is under review by the U.S. Food and Drug Administration (FDA).

Vascade is a fully integrated, extravascular, bioabsorbable femoral access closure system that leaves no permanent components behind, and has demonstrated safety and efficacy in a wide range of patients. The system combines Cardiva’s proprietary collapsible disc technology and a thrombogenic resorbable collagen patch in an integrated design. For patients and healthcare providers, Vascade enables secure and rapid hemostasis while minimizing complications, including bleeding at the access site.

Vascade works by placing a small, collapsible mesh disc against the inside of the vessel wall to temporarily stop the bleeding, releasing a collagen patch into the tissue and then removing the mesh disc. The collagen patch expands, providing a mechanical and physiological seal to stop the bleeding, and then absorbs into the body, leaving nothing behind and allowing further access to the vessel if additional procedures are required.

For more information: www.cardivamedical.com

 

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init